- In April 2023, Pfizer Inc. announced the global expansion of Zavegepant, its intranasal CGRP receptor antagonist, into several new international markets following regulatory approvals. The drug’s rapid-onset intranasal formulation addresses acute migraine attacks more efficiently, especially for patients unable to take oral medications. This move reinforces Pfizer’s commitment to diversifying migraine treatment options and expanding access to fast-acting therapies worldwide
- In March 2023, Biohaven Ltd., in collaboration with Royalty Pharma, launched an expanded access program for Rimegepant in emerging markets. This initiative aims to address the high unmet need for migraine treatment by providing oral CGRP antagonist therapy in regions with limited access. The effort demonstrates Biohaven’s strategic emphasis on global health equity and its dedication to making innovative treatments more accessible to underserved populations
- In March 2023, Eli Lilly and Company received extended European Medicines Agency (EMA) approval for Emgality (galcanezumab) for the treatment of cluster headaches in addition to migraine prevention. The expansion of approved indications marks a significant milestone in the CGRP space, highlighting the drug's therapeutic versatility and Lilly’s continued leadership in neurology-focused biologics
- In February 2023, Teva Pharmaceuticals launched a real-world evidence (RWE) initiative to assess the long-term outcomes of Ajovy (fremanezumab) in migraine patients across North America and Europe. This program aims to provide robust post-market data on the safety, effectiveness, and patient-reported satisfaction of CGRP monoclonal antibodies, supporting the clinical value proposition of CGRP-targeted therapies in diverse healthcare systems
- In January 2023, AbbVie Inc. presented positive Phase 3 trial results for Atogepant, a once-daily oral CGRP receptor antagonist, demonstrating its efficacy in the preventive treatment of chronic migraine. These results reinforce AbbVie’s growing presence in the CGRP market and its commitment to addressing both episodic and chronic forms of migraine with differentiated, patient-centric therapies
